Novartis AG annual free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Novartis AG Free Cash Flow (FCF) History (NVS)
Novartis AG reported $17.60B in free cash flow for fiscal 2025, an increase of 8.26% from the previous fiscal year, with a free cash flow margin of 32.27%.
View full Novartis AG company overviewNovartis AG free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $17.60B | $1.34B | +8.26% | +32.27% |
| 2024 | 2024-12-31 | $16.25B | $2.85B | +21.31% | +32.30% |
| 2023 | 2023-12-31 | $13.40B | $78.0M | +0.59% | +29.49% |
| 2022 | 2022-12-31 | $13.32B | −$685.0M | −4.89% | +31.56% |
| 2021 | 2021-12-31 | $14.01B | $1.63B | +13.17% | +32.74% |
| 2020 | 2020-12-31 | $12.38B | $129.0M | +1.05% | +25.43% |
| 2019 | 2019-12-31 | $12.25B | −$772.0M | −5.93% | +25.78% |
| 2018 | 2018-12-31 | $13.02B | $1.72B | +15.24% | +29.04% |
| 2017 | 2017-12-31 | $11.30B | $1.68B | +17.51% | +26.65% |
| 2016 | 2016-12-31 | $9.61B | — | — | +19.81% |
Novartis AG quarterly free cash flow
Q2.17
Q2.18
Q2.19
Q2.20
Q2.21
Q2.22
Q2.23
Q2.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.12B | −$1.21B | −19.09% | +34.27% |
| Q1 2026 | 2026-03-31 | $2.87B | — | — | +21.21% |
| Q4 2025 | 2025-12-31 | $1.25B | — | — | +9.00% |
| Q3 2025 | 2025-09-30 | $5.74B | — | — | +39.98% |
| Q2 2025 | 2025-06-30 | $6.33B | $1.72B | +37.23% | +45.06% |
| Q2 2024 | 2024-06-30 | $4.62B | $1.26B | +37.72% | +36.88% |
| Q2 2023 | 2023-06-30 | $3.35B | −$147.0M | −4.20% | +29.30% |
| Q2 2022 | 2022-06-30 | $3.50B | −$313.0M | −8.21% | +27.37% |
| Q2 2021 | 2021-06-30 | $3.81B | $88.0M | +2.36% | +29.41% |
| Q2 2020 | 2020-06-30 | $3.72B | $891.0M | +31.46% | +32.81% |
| Q2 2019 | 2019-06-30 | $2.83B | −$853.0M | −23.15% | +24.07% |
| Q2 2018 | 2018-06-30 | $3.69B | $435.0M | +13.38% | +32.44% |
| Q2 2017 | 2017-06-30 | $3.25B | — | — | +26.55% |
Novartis AG free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from $12.38B to $17.60B, a compound annual growth rate of 7.29%. Novartis AG's latest reported quarter, Q2 2026, generated $5.12B in free cash flow, a decrease of 19.09% year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Novartis AG source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...
